Nestlé S.A. completed the acquisition of Zenpep and Viokace from Allergan plc.
On March 17, 2020, Allergan and AbbVie have entered into a consent decree agreement with staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie's pending acquisition of Allergan. Under the terms of the consent decree, the companies have agreed to divest brazikumab and Zenpep. The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC. The deal is expected to be finalized concurrent with the merger of Allergan and AbbVie. The closing of the Allergan and AbbVie transaction is expected in the first-quarter of 2020. As on March 17, 2020, Allergan and AbbVie anticipate closing in May 2020.
Jonathan L. Davis, Eric L. Schiele, Sophia Hudson, and James F. Hurst of Kirkland & Ellis LLP and Andrew Bab, Jennifer Chu, Sue Meng, Thomas Schürrle, Molly Stockley, Gary Friedman, Jonathan Lewis, Henry Lebowitz and Paul Rubin of Debevoise & Plimpton LLP acted as legal advisors to Allergan plc. David Carpenter, John Boelter, Reb Wheeler, Joseph Mahoney, Richard Assmus, Remmelt Reigersman, Elizabeth Mann, Mark Ryan, Adam Hudes and Meytal McCoy of Mayer Brown acted as legal advisor to Nestlé.
Nestlé S.A. (SWX:NESN) completed the acquisition of Zenpep and Viokace from Allergan plc (NYSE:AGN) on May 11, 2020.